
James K. Mooney
Examiner (ID: 9373)
| Most Active Art Unit | 2655 |
| Art Unit(s) | 2654, 2655, 2695 |
| Total Applications | 772 |
| Issued Applications | 554 |
| Pending Applications | 72 |
| Abandoned Applications | 168 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14867921
[patent_doc_number] => 20190284202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-19
[patent_title] => PROCESS FOR THE MANUFACTURE OF DIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/434438
[patent_app_country] => US
[patent_app_date] => 2019-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6252
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16434438
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/434438 | PROCESS FOR THE MANUFACTURE OF DIAZEPINE DERIVATIVES | Jun 6, 2019 | Abandoned |
Array
(
[id] => 15293495
[patent_doc_number] => 20190389883
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES
[patent_app_type] => utility
[patent_app_number] => 16/433117
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38353
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433117
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433117 | Methods of preparing cytotoxic benzodiazepine derivatives | Jun 5, 2019 | Issued |
Array
(
[id] => 17954476
[patent_doc_number] => 11480576
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-25
[patent_title] => Conjugated oligomer-based macrocycles for live cell imaging
[patent_app_type] => utility
[patent_app_number] => 16/433243
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 22
[patent_no_of_words] => 6372
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16433243
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/433243 | Conjugated oligomer-based macrocycles for live cell imaging | Jun 5, 2019 | Issued |
Array
(
[id] => 20701326
[patent_doc_number] => 12624026
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-05-12
[patent_title] => Inhibitors of SARM1
[patent_app_type] => utility
[patent_app_number] => 16/972670
[patent_app_country] => US
[patent_app_date] => 2019-06-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 23909
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16972670
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/972670 | INHIBITORS OF SARM1 | Jun 5, 2019 | Issued |
Array
(
[id] => 18102363
[patent_doc_number] => 11542238
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-03
[patent_title] => Pyrimidine cyclohexenyl glucocorticoid receptor modulators
[patent_app_type] => utility
[patent_app_number] => 15/734525
[patent_app_country] => US
[patent_app_date] => 2019-06-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 27786
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 303
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15734525
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/734525 | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | Jun 2, 2019 | Issued |
Array
(
[id] => 17006978
[patent_doc_number] => 20210238139
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => MODULATORS OF TRYPTOPHAN CATABOLISM
[patent_app_type] => utility
[patent_app_number] => 17/054885
[patent_app_country] => US
[patent_app_date] => 2019-05-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57002
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054885
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/054885 | MODULATORS OF TRYPTOPHAN CATABOLISM | May 30, 2019 | Abandoned |
Array
(
[id] => 16932301
[patent_doc_number] => 20210198190
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-01
[patent_title] => NOVEL SUBSTITUTED [1.1.1] BICYCLO COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/057921
[patent_app_country] => US
[patent_app_date] => 2019-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13251
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057921
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/057921 | Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors | May 27, 2019 | Issued |
Array
(
[id] => 15178033
[patent_doc_number] => 20190359608
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-28
[patent_title] => TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
[patent_app_type] => utility
[patent_app_number] => 16/421881
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61907
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 2320
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421881
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/421881 | Tricyclic heterocyclic compounds as sting activators | May 23, 2019 | Issued |
Array
(
[id] => 16869962
[patent_doc_number] => 20210163429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => P-PHENYLENEDIAMINE DERIVATIVE AS POTASSIUM CHANNEL REGULATOR AND PREPARATION METHOD AND MEDICAL APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/057457
[patent_app_country] => US
[patent_app_date] => 2019-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 194
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17057457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/057457 | P-phenylenediamine derivative as potassium channel regulator and preparation method and medical application thereof | May 21, 2019 | Issued |
Array
(
[id] => 14808171
[patent_doc_number] => 20190270695
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => PROCESS FOR THE PREPARATION OF AN ANTIBODY-RIFAMYCIN CONJUGATE
[patent_app_type] => utility
[patent_app_number] => 16/415612
[patent_app_country] => US
[patent_app_date] => 2019-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9574
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16415612
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/415612 | Process for the preparation of an antibody-rifamycin conjugate | May 16, 2019 | Issued |
Array
(
[id] => 16962834
[patent_doc_number] => 20210214333
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING
[patent_app_type] => utility
[patent_app_number] => 17/054850
[patent_app_country] => US
[patent_app_date] => 2019-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57528
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054850
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/054850 | Substituted condensed thiophenes as modulators of sting | May 15, 2019 | Issued |
Array
(
[id] => 15253997
[patent_doc_number] => 20190375732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/412319
[patent_app_country] => US
[patent_app_date] => 2019-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50842
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16412319
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/412319 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | May 13, 2019 | Abandoned |
Array
(
[id] => 15290837
[patent_doc_number] => 20190388554
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-26
[patent_title] => PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/412138
[patent_app_country] => US
[patent_app_date] => 2019-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37934
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16412138
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/412138 | Pyrrolobenzodiazepines and conjugates thereof | May 13, 2019 | Issued |
Array
(
[id] => 15147587
[patent_doc_number] => 20190352271
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => MCL-1 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/410457
[patent_app_country] => US
[patent_app_date] => 2019-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97371
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16410457
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/410457 | MCL-1 inhibitors | May 12, 2019 | Issued |
Array
(
[id] => 16230512
[patent_doc_number] => 10738050
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-08-11
[patent_title] => 4H-pyrido[1,2-A]pyrimidin-4-one compounds
[patent_app_type] => utility
[patent_app_number] => 16/409296
[patent_app_country] => US
[patent_app_date] => 2019-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29440
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 209
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409296
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/409296 | 4H-pyrido[1,2-A]pyrimidin-4-one compounds | May 9, 2019 | Issued |
Array
(
[id] => 14777865
[patent_doc_number] => 20190263830
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN
[patent_app_type] => utility
[patent_app_number] => 16/409398
[patent_app_country] => US
[patent_app_date] => 2019-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5485
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409398
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/409398 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN | May 9, 2019 | Abandoned |
Array
(
[id] => 14777863
[patent_doc_number] => 20190263829
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-29
[patent_title] => POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN
[patent_app_type] => utility
[patent_app_number] => 16/409324
[patent_app_country] => US
[patent_app_date] => 2019-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 6
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16409324
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/409324 | POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN | May 9, 2019 | Abandoned |
Array
(
[id] => 16777987
[patent_doc_number] => 20210115064
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-22
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/054118
[patent_app_country] => US
[patent_app_date] => 2019-05-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11319
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054118
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/054118 | Compositions and methods for treating cancer | May 7, 2019 | Issued |
Array
(
[id] => 17022256
[patent_doc_number] => 20210246127
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-12
[patent_title] => COMPOUNDS AND METHODS TARGETING GPER FOR TREATMENT OF DISEASES ASSOCIATED WITH CALCIUM
[patent_app_type] => utility
[patent_app_number] => 17/052584
[patent_app_country] => US
[patent_app_date] => 2019-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -58
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052584
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/052584 | Compounds and methods targeting GPER for treatment of diseases associated with calcium | May 2, 2019 | Issued |
Array
(
[id] => 17307317
[patent_doc_number] => 11208409
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Substituted xanthines and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/397697
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61155
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397697
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/397697 | Substituted xanthines and methods of use thereof | Apr 28, 2019 | Issued |